Recently hydrophilic poly[N-(2-hydroxypropyl)
methacrylamide] (PHPMA) was used for
BS-RNase modification to prevent its degradation in bloodstream or fast elimination.
Polymer-conjugated
BS-RNase preparations proved to be cytotoxic after intravenous or intraperitoneal application, whereas native
BS-RNase was ineffective. Here
RNase A unimer was conjugated with two
HPMA polymers (classic and star) and their antitumor effects both in vitro and in vivo were compared with those of
BS-RNase polymers. Surprisingly, the antitumor effect of
RNase A conjugates was also pronounced. The
RNase A conjugates (classic and star) injected intravenously to mice bearing
melanoma tumor caused a significant reduction in
tumor volume following ten doses of 5 and 1 mg/kg, respectively. Despite the antitumor activity observed in vivo, the in vitro tested cytotoxic activity of
RNase A did not differ from that caused by native
RNase A while native
BS-RNase (50 microg/ml) totally inhibited
DNA synthesis in treated cells. The experiments with 125I-labeled preparations demonstrated concentration-dependent internalization of native
BS-RNase by
tumor cells within an hour, whereas the
polymer conjugate (S-BS) was not internalized. On the contrary, the in vivo experiments showed that whereas 40% of S-BS conjugate persisted in bloodstream for 24h after administration, 98% of the native
BS-RNase was already eliminated. Improved antitumor activities of PHPMA-modified RNases in vivo might be ascribed to their prolonged retention in bloodstream, better proteolytic stability and resistance to the action of the
ribonuclease inhibitor.